• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4673303)   Today's Articles (372)
For: Saxena A, Jain GK, Siddiqui HH, Bhunia SS, Saxena AK, Gayen JR. In vitrometabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies. Xenobiotica 2013;44:295-308. [PMID: 23992115 DOI: 10.3109/00498254.2013.831958] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Number Cited by Other Article(s)
1
Bhateria M, Rachumallu R, Yerrabelli S, Saxena AK, Bhatta RS. Insight into stereoselective disposition of enantiomers of a potent antithrombotic agent, S002-333 following administration of the racemic compound to mice. Eur J Pharm Sci 2017;101:107-114. [DOI: 10.1016/j.ejps.2017.02.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 02/06/2017] [Accepted: 02/06/2017] [Indexed: 11/30/2022]
2
Bhunia SS, Misra A, Khan IA, Gaur S, Jain M, Singh S, Saxena A, Hohlfield T, Dikshit M, Saxena AK. Novel Glycoprotein VI Antagonists as Antithrombotics: Synthesis, Biological Evaluation, and Molecular Modeling Studies on 2,3-Disubstituted Tetrahydropyrido(3,4-b)indoles. J Med Chem 2016;60:322-337. [DOI: 10.1021/acs.jmedchem.6b01360] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
3
Bhateria M, Ramakrishna R, Puttrevu SK, Yerrabelli S, Saxena AK, Bhatta RS. Pre-clinical investigation of plasma pharmacokinetics and biodistribution of a novel antithrombotic agent S002-333 in mice using LC–MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1031:154-162. [DOI: 10.1016/j.jchromb.2016.07.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 07/11/2016] [Accepted: 07/17/2016] [Indexed: 11/27/2022]
4
Bhateria M, Ramakrishna R, Puttrevu SK, Saxena AK, Bhatta RS. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6. Chem Biol Interact 2016;256:257-65. [DOI: 10.1016/j.cbi.2016.07.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Revised: 06/13/2016] [Accepted: 07/03/2016] [Indexed: 10/21/2022]
5
Saxena A, Valicherla GR, Jain GK, Bhatta RS, Saxena AK, Gayen JR. Metabolic profiling of a novel antithrombotic compound, S002-333 and enantiomers: metabolic stability, species comparison andin vitro-in vivoextrapolation. Biopharm Drug Dispos 2016;37:185-99. [DOI: 10.1002/bdd.1995] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 10/01/2015] [Accepted: 10/12/2015] [Indexed: 11/07/2022]
6
Fang L, Lin CX, Zhu ZW, Zhao LS, Zhang SY. Elucidation of in vitro phase I metabolites of droperidol using UPLC-QTOF MS. Eur J Drug Metab Pharmacokinet 2015;40:111-4. [PMID: 24590313 DOI: 10.1007/s13318-014-0185-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Accepted: 02/21/2014] [Indexed: 02/05/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA